Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both

Journal of Clinical Neuroscience

Volumn 16, Issue 1, 2009, Pages 83-87

  Ozer, Feriha ^a   Tiras, Raziye ^a   Cetin, Sibel ^a   Ozturk, Oya ^a   Aydemir, Tuba ^a   Ozben, Serkan ^a   Meral, Hasan ^a   Kizkin, Sibel ^b   Bader, Halit ^c   Ozben, Beste ^d  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c Kizilay Medical Center   (Turkey)

^d MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Levodopa; Parkinson's disease; Pergolide; Valvulopathy

Indexed keywords

LEVODOPA; PERGOLIDE;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MONOTHERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ADULT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE DISEASES; HUMANS; LEVODOPA; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 57049117301     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.02.005     Document Type: Article

References (23)

1. Shaunak S., Wilkins A., Pilling J.B., et al. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 66 (1999) 79-81
2. Pritchett A.M., Morrison J.F., Edwards W.D., et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 (2002) 1280-1286
3. Van Camp G., Flamez A., Cosyns B., et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 61 (2003) 859-861
4. Van Camp G., Flamez A., Cosyns B., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 (2004) 1179-1183
5. Horvath J., Fross R.D., Kleiner-Fisman G., et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19 (2004) 656-662
6. Baseman D.G., O'Suilleabhain P.E., Reimold S.C., et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63 (2004) 301-304
7. Bana D.S., MacNeal P.S., LeCompte P.M., et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88 (1974) 640-655
8. Redfield M.M., Nicholson W.J., Edwards W.D., et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117 (1992) 50-52
9. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
10. Robiolio P.A., Rigolin V.H., Wilson J.S., et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnmalities detected by cardiac catheterization and echocardiography. Circulation 92 (1995) 790-795
11. Rothman R.B., Baumann M.H., Savage J.E., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
12. Millan M.J., Maiofiss L., Cussac D., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303 (2002) 791-804
13. Fahn S., and Elton R. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent developments in Parkinson's disease Vol. 1 (1987), MacMillan Healthcare Information, New Jersey 153-163
14. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
15. Zoghbi W.A., Enriquez-Sarano M., Foster E., et al. American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 (2003) 777-802
16. Quiñones M.A., Otto C.M., Stoddard M., et al. Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15 (2002) 167-184
17. Bonow R.O., Carabello B., de Leon Jr. A.C., et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98 (1998) 1949-1984
18. VanAuker M.D. Age-related changes in hemodynamics affecting valve performance. Am J Geriatr Cardiol 15 (2006) 277-283
19. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 (1997) 630-634
20. Waller E.A., Kaplan J., and Heckman M.G. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80 (2005) 1016-1020
21. Peralta C., Wolf E., Alber H., et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 21 (2006) 1109-1113
22. Singh J.P., Evans J.C., Levy D., et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83 (1999) 897-902
23. Kim J.Y., Chung E.J., Park S.W., et al. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 21 (2006) 1261-1264